Related Experiment Video
Updated: Jun 19, 2026

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
Published on: September 20, 2024
Update on antibiotics for infection control in cystic fibrosis
Stephen Kirkby1, Kimberly Novak, Karen McCoy
1Section of Pulmonary Medicine, Nationwide Children's Hospital, Ohio State University Medical Center, Columbus, OH 43205, USA. stephen.kirkby@nationwidechildrens.org
Abstract:
Cystic fibrosis pulmonary disease is characterized by chronic and recurrent infection, airway inflammation, bronchiectasis and progressive obstructive lung physiology. Advances in the treatment of common airway pathogens such as Pseudomonas aeruginosa have led to a marked improvement in overall survival. However, antibiotic treatment options are often limited by multidrug resistance, potential toxicities and treatment burden to individual patients. While appropriate anti-infective therapy reduces bacterial density in the airways and may result in clinical improvement, true eradication of airway infection is seldom achieved except for early-stage infections. This review summarizes current approaches for acute and chronic anti-infective therapy in cystic fibrosis.
Insights
Cystic fibrosis lung infections, like Pseudomonas aeruginosa, are hard to eradicate. This review covers current anti-infective strategies for acute and chronic infections in cystic fibrosis patients.
Area of Science:
- Pulmonary Medicine
- Infectious Diseases
- Cystic Fibrosis Research
Background:
- Cystic fibrosis lung disease involves chronic infections, inflammation, and airway obstruction.
- Pseudomonas aeruginosa is a common pathogen in cystic fibrosis, with improved survival due to treatments.
- Antibiotic resistance, toxicity, and treatment burden limit current anti-infective options.
Purpose of the Study:
- To review current anti-infective therapy approaches for cystic fibrosis.
- To discuss challenges in eradicating airway infections in cystic fibrosis.
- To summarize strategies for acute and chronic infections.
Main Methods:
- Literature review of anti-infective therapies in cystic fibrosis.
- Analysis of treatment options for Pseudomonas aeruginosa and other common pathogens.
- Summary of current clinical practices and challenges.
Main Results:
- Anti-infective therapy can reduce bacterial load and improve clinical status.
- Complete eradication of airway infections is rarely achieved, except in early stages.
- Multidrug resistance and treatment limitations impact therapeutic effectiveness.
Conclusions:
- Current anti-infective strategies offer improvements but face significant challenges.
- Further research is needed to overcome resistance and improve eradication rates.
- Optimizing acute and chronic anti-infective therapy remains critical for cystic fibrosis patients.
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Mechanism of Antibiotic Resistance in MRSA
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Inhibitors of Bacterial DNA Synthesis
Urine Studies II: Urine Culture and Sensitivity Test

